Clinical Research

Clinical Research

Dr. Fisher has held teaching and administrative appointments. At present he serves as the Chief of the Division of Rheumatology at Our Lady of Lourdes Medical Center in Camden, NJ, Chief of the Division of Rheumatology at Kessler Memorial Hospital in Hammonton, NJ, and Clinical Assistant Professor of Medicine Thomas Jefferson University Hospital in Philadelphia, PA.

For the past 20 years, Dr. Fisher has been involved in clinical research trials as a Primary Investigator. He has participated in phase 2, 3 and 4 clinical trials for osteoporosis, analgesics, NSAIDS COX2s for osteoarthritis and rheumatoid arthritis, GI tolerability, pain management, low back pain, and IV biologics for rheumatoid arthritis.

Jill Stubbs, CCRC

Ms. Jill Stubbs has served as Director and Coordinator of Fisher Clinical Research since 2002. Her responsibilities include all aspects of Quality Assurance and Regulatory Affairs, and coordination of patient care and documentation, EKGs and phlebotomy.

Ms. Stubbs received her clinical research coordinator certification from the ACRP, Association of Clinical Research Professionals. She is certified in accordance with DATA guidelines for the shipping of dangerous goods. She has extensive training in the medical equipment required for therapeutic trials. She has twenty years of experience in the medical field, eight of which have been in clinical research and clinical trials.

Contact Jill Stubbs : fisherresearch@markfishermd.com

Facility

Fisher Clinical Research has a full time dedicated staff to assist with the patients’ needs. The office is conveniently located in Haddon Heights, NJ where it is easily accessible by I-295 and the White Horse Pike (Route 30). All patients are treated with the highest level of courtesy and accommodation. Referrals from physicians are appreciated and treated with confidentiality. No patients seen on referral for our clinical trials will be seen in the office for rheumatic care outside of the clinical trial unless the referring physician personally calls and requests it. This is the policy of the Center in order to avoid all conflicts of interest and the relationship of the referring physicians and their patients.

Current Studies with Active Enrollment:
Rheumatoid Arthritis:
Active RA multiple joints. Multiple tender and swollen joints. No previous biologic agents. Current medication includes methotrexate.

New trial for rheumatoid arthritis for patients not currently on methotrexate and that have not had prior treatment with a biologic, injectable medication in the past.New trial for rheumatoid arthritis for patients on methotrexate. Patients had to fail prior treatment with a biologic, injectable medication in the past.

 
Recently Completed Studies:
New clinical trial on a new oral agent for the treatment of rheumatoid arthritis for patients also on methotrexate- a 3 month trial for patients over age 18 years

SB-767905/011:
Double-Blind, Placebo-Controlled, Multicenter Phase IIB Study to Evaluate Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Pain.

ABD104225:
Prospective, Observational Study, to Characterize GI Function and Morbidity, and the Humanistic Burden of Illness Among Opioid-Naïve Subjects With Pain Treated With Opioid Therapy.

Voltar Study:
Twelve patients were enrolled for a Phase III clinical trial of Voltaren, a new NSAID.

Nabumetone Study:
Study comparing a new NSAID, Nabumetone, to another NSAID in a Phase III clinical trial.

Treazolam and Temazepam:
Insomnia treatment study, comparing Treazolam and Temazepam.
 
Mucosa Trial:
Double blind study evaluating Cytotec plus NSAID and the risk of GI
complications.

Ultram Study:
Randomized study comparing Ultram to NSAID and narcotic analgesics for pain.

Rheumatoid Arthritis Study:
A double blind, randomized, parallel group, multicenter comparison of the efficacy and safety of Mycophenolate mofetil p.o. (Xg b.i.d.) and placebo in patients with active rheumatoid arthritis (six month efficacy study) who are candidates for immunosuppressive therapy for rheumatoid arthritis.

Meloxicam Study:
A multicenter, double blind, double dummy, randomized, parallel group trial to compare the efficacy and safety of three doses of Meloxicam (X, X and Xmg) with XXX (X mg) and placebo in patients with osteoarthritis.

Meloxicam Study:
A multicenter, double blind, double dummy, randomized, parallel group trial to compare the efficacy and safety of three doses of Meloxicam with Naproxen and placebo on patients with rheumatoid arthritis.

Rofecoxib Study:
Randomized double blind multicenter study evaluating the tolerability and effectiveness of Rofecoxib versus Naproxen in patients with rheumatoid arthritis.

Rofecoxib Study:
Randomized double blind multicenter study evaluating the tolerability and effectiveness of Rofecoxib versus Naproxen in patients with osteoarthritis.

Naltrexone HCI
A multicenter, Randomized, Double-Blind, Active-and Placebo-Controlled, Phase lll, Effacacy and Safety Study of Oxycodone HCI and Low-Dose Naltrexone HCI( in Patients with Moderate to Severe Chronic Pain due to Osteoarthritis of the Hip or Knee.

Diclofenac Sodium Gel
Randomized, double-blind multi-centered, vehicle-controlled, parallel group study to assess the efficacy and safety of the Diclofenac Sodium Gel 1%
For the relief of signs and symptoms in patients with osteoarthritis of the knee.

DOV-075-020-US
Double blind, placebo-controlled randomized study of Bicifadine in the treatment of Chronic Low Back Pain

MK0663
A Randomized Double Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients with Osteoarthritis and Rhematoid Arthritis.

MK-0663
A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib vs. Diclofenac Sodium in Patients with Rheumatoid Arthritis.

MK-0663
26 Week Randomized, Placebo-and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2 Part study to Assess the Safety and Effacacy of Etoricoxib vs Celecoxib in Patients with Osteoarthritis.

RADIUS 1 Study
Rheumatoid Arthritis DMARD Intervention and UtilizationStudy.

OXY4003 STUDY
Multicenter Usual Care Open-Labeled Randomized-Parallel-Group Trial Comparing the Impact of Therapy with Oxycontin vs. Usual Care in Moderate to Severe Osteoarthritis of the Hip or Knee.

SB-767905/011
Double-Blind, Placebo-Controlled, Multicenter Phase IIB Study to Evaluate Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Pain.

ABD104225
Prospective, Observational Study, to Characterize GI Function and Morbidity, and the Humanistic Burden of Illness Among Opioid-Naïve Subjects With Pain Treated With Opioid Therapy.

PTI-801-XH
A Multi-center, Randomized, Double-Blind, Active- and Placebo-Controlled, Phaselll, Efficacy and Safety Study of Oxycodone HCI and Low Dose Naltrexone HCI in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee.

VOSG-PN-310
A 12 Week, Randomized, Double-Blind, Multicenter, Vehicle-Controlled, Parallel Group To Assess the Efficacy and Safety of the Diclofenic Sodium Gel 1% for the Relief of Signs and Symptoms in Patients with Osteoarthritis of the Knee.

SB/767905-012/014
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan for 12 Weeks and 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.

MDT3-005
A Two-Arm study Comparing the Analgesic Efficacy and Safety of Tramadol HCI Once-a-Day Versus Placebo for the Treatment of Pain Due to Osteoarthritis.

A3191172
Bothered by Arthritis?
Concerned About Heart Disease?
Learn about a new research study especially for patients with arthritis who have or are at risk for heart disease.

A7701005
Are you taking Methotrexate for your Rheumatoid Arthritis? Do your symptoms still bother you?
We are seeking men and women who are taking methotrexate for rheumatoid arthritis but are still experiencing symptoms of stiff, tender and swollen joints to take part in a research study.
 
The purpose of this research is to evaluate the effectiveness of an investigational medication on controlling the signs and symptoms of rheumatoid arthritis when taken in addition to methotrexate.

Participants must:

CRx-102-007
Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. RA is a disease that affects all ages and is typically characterized by stiffness, pain, swollen joints and disability.
If you have been diagnosed with rheumatoid arthritis, you may qualify to participate in a clinical research study.

If you have any questions, pelase call 856-547-8004 Ext: 13

Clinical Research

Clinical Research

Clinical Research

Mark Fisher, M.D. F.A.C.R.

Dr. Mark Fisher is board certified in Rheumatology and is a Fellow of the American College of Rheumatology. He received his medical degree in 1973 from Hahnemann Medical College in Philadelphia, PA. He completed his residency program in Internal Medicine at Hahnemann Hospital. Dr. Fisher performed a fellowship in Rheumatology at Temple University Hospital in Philadelphia, PA.